Skip to main content

Prognostic, predictive, and surrogate factors for individualizing treatment for men with castration-resistant prostate cancer.

Publication ,  Journal Article
Bitting, RL; Armstrong, AJ
Published in: Am Soc Clin Oncol Educ Book
2012

With the surge in therapeutic options for castration-resistant prostate cancer (CRPC) comes increasingly complicated treatment decision making, highlighting the need for biomarkers that can identify appropriate patients for specific treatments and accurately assess disease response. Here we discuss existing and potential prognostic, predictive, and surrogate biomarkers in CRPC.

Duke Scholars

Published In

Am Soc Clin Oncol Educ Book

DOI

ISSN

1548-8748

Publication Date

2012

Start / End Page

292 / 297

Location

United States

Related Subject Headings

  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bitting, R. L., & Armstrong, A. J. (2012). Prognostic, predictive, and surrogate factors for individualizing treatment for men with castration-resistant prostate cancer. Am Soc Clin Oncol Educ Book, 292–297. https://doi.org/10.14694/EdBook_AM.2012.32.24
Bitting, Rhonda L., and Andrew J. Armstrong. “Prognostic, predictive, and surrogate factors for individualizing treatment for men with castration-resistant prostate cancer.Am Soc Clin Oncol Educ Book, 2012, 292–97. https://doi.org/10.14694/EdBook_AM.2012.32.24.
Bitting, Rhonda L., and Andrew J. Armstrong. “Prognostic, predictive, and surrogate factors for individualizing treatment for men with castration-resistant prostate cancer.Am Soc Clin Oncol Educ Book, 2012, pp. 292–97. Pubmed, doi:10.14694/EdBook_AM.2012.32.24.

Published In

Am Soc Clin Oncol Educ Book

DOI

ISSN

1548-8748

Publication Date

2012

Start / End Page

292 / 297

Location

United States

Related Subject Headings

  • 3211 Oncology and carcinogenesis